Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873275 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL28950324 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL11214491 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL27587142 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL14313876 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL8527396 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL3395699 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL9413358 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL9413366 | 1.00 | USP2 (0.56) | USP2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL11038387 | 0.98 | USP2 (0.55) | USP2LMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3914232-A1 | LIPID VESICLE FOR ORAL DRUG DELIVERY | F. Hoffmann-La Roche AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152303-A1 | LIPID VESICLE FOR ORAL DRUG DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-30 | — | — | WO | disclosed |
| EP-3620519-A1 | USE OF ISOLATED MILK EXTRACELLULAR VESICLES FOR DELIVERING OLIGONUCLEOTIDES ORALLY | F. Hoffmann-La Roche AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-10443058-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-10-15 | — | — | US | disclosed |
| US-10370668-B2 | Manufacture of antisense oligomers and conjugates targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| EP-3406718-A1 | OLIGONUCLEOTIDE CONJUGATES | Roche Innovation Center Copenhagen A/S (DK) | 2018-11-28 | — | — | EP | disclosed |
| WO-2015071388-A1 | APOB ANTISENSE CONJUGATE COMPOUNDS | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014207232-A1 | ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9 | SANTARIS PHARMA A/S (DK) | 2014-12-31 | — | — | WO | disclosed |
| EP-2768925-A1 | LIGHT SOURCE WITH QUANTUM DOTS | Koninklijke Philips N.V. (NL) | 2014-08-27 | — | — | EP | disclosed |
| WO-2014118267-A1 | LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | SANTARIS PHARMA A/S (DK) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014076195-A1 | OLIGONUCLEOTIDE CONJUGATES | SANTARIS PHARMA A/S (DK) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076196-A1 | ANTI APOB ANTISENSE CONJUGATE COMPOUNDS | SANTARIS PHARMA A/S (DK) | 2014-05-22 | — | — | WO | disclosed |
| WO-2013057702-A1 | LIGHT SOURCE WITH QUANTUM DOTS | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2013-04-25 | — | — | WO | disclosed |
| WO-2006031461-A2 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005113571-A2 | METHODS FOR THE DELIVERY OF OLIGOMERIC COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2004044141-A2 | CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | USP2 4081/4885LMNA 572/4885KDM4E 1639/4885 |
| US-10443058-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | USP2 3255/4885LMNA 199/4885KDM4E 4054/4885 |
| US-10370668-B2 | Manufacture of antisense oligomers and conjugates targeting PCSK9 | PCSK9, PCSK7, PCSK6 | USP2 3568/4885LMNA 194/4885KDM4E 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.